65.36
0.63%
+0.41
After Hours:
62.35
-3.01
-4.61%
ANI Pharmaceuticals Inc stock is currently priced at $65.36, with a 24-hour trading volume of 66,012.
It has seen a +0.63% increased in the last 24 hours and a -6.02% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $64.84 pivot point. If it approaches the $65.39 resistance level, significant changes may occur.
Previous Close:
$64.95
Open:
$64.83
24h Volume:
66,012
Market Cap:
$1.37B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
-136.17
EPS:
-0.48
Net Cash Flow:
$100.45M
1W Performance:
-0.18%
1M Performance:
-6.02%
6M Performance:
+8.07%
1Y Performance:
+73.78%
ANI Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
ANI Pharmaceuticals Inc
Sector
Phone
218-634-3500
Address
210 Main Street West, Baudette, MN
ANI Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
Mar-01-23 | Initiated | Guggenheim | Buy |
Sep-07-22 | Initiated | H.C. Wainwright | Buy |
Nov-02-21 | Initiated | Truist | Buy |
May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-12-19 | Initiated | Guggenheim | Buy |
May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
Jul-31-17 | Initiated | Canaccord Genuity | Buy |
Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
Jun-23-16 | Initiated | Raymond James | Strong Buy |
May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
Nov-13-15 | Initiated | Standpoint Research | Buy |
Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
Aug-05-15 | Reiterated | Oppenheimer | Outperform |
Aug-04-15 | Reiterated | ROTH Capital | Neutral |
Jul-31-15 | Reiterated | Oppenheimer | Outperform |
Jul-15-15 | Reiterated | ROTH Capital | Neutral |
Jun-23-15 | Reiterated | Oppenheimer | Outperform |
May-18-15 | Reiterated | ROTH Capital | Neutral |
May-06-15 | Reiterated | Oppenheimer | Outperform |
Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
Feb-26-15 | Reiterated | ROTH Capital | Buy |
Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
ANI Pharmaceuticals Inc Stock (ANIP) Latest News
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Zacks Investment Research
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Zacks Investment Research
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks Investment Research
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
Zacks Investment Research
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Zacks Investment Research
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
Benzinga
ANI Pharmaceuticals Inc Stock (ANIP) Financials Data
ANI Pharmaceuticals Inc (ANIP) Revenue 2024
ANIP reported a revenue (TTM) of $486.82 million for the quarter ending December 31, 2023, a +53.87% rise year-over-year.
ANI Pharmaceuticals Inc (ANIP) Net Income 2024
ANIP net income (TTM) was $18.78 million for the quarter ending December 31, 2023, a +139.21% increase year-over-year.
ANI Pharmaceuticals Inc (ANIP) Cash Flow 2024
ANIP recorded a free cash flow (TTM) of $100.45 million for the quarter ending December 31, 2023, a +310.77% increase year-over-year.
ANI Pharmaceuticals Inc (ANIP) Earnings per Share 2024
ANIP earnings per share (TTM) was $0.82 for the quarter ending December 31, 2023, a +126.97% growth year-over-year.
ANI Pharmaceuticals Inc Stock (ANIP) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS |
Apr 18 '24 |
Sale |
64.98 |
10,423 |
677,287 |
799,429 |
Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS |
Apr 17 '24 |
Sale |
65.40 |
9,520 |
622,608 |
809,852 |
Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS |
Apr 16 '24 |
Sale |
66.20 |
5,834 |
386,211 |
819,372 |
Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS |
Apr 15 '24 |
Sale |
66.33 |
7,414 |
491,771 |
825,206 |
Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Apr 12 '24 |
Sale |
67.79 |
250 |
16,948 |
59,731 |
Gassert Chad | SVP - CORP. DEV. & STRATEGY |
Apr 01 '24 |
Sale |
67.25 |
20,000 |
1,345,000 |
253,226 |
Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
Mar 13 '24 |
Sale |
66.54 |
250 |
16,635 |
59,981 |
Gassert Chad | SVP - CORP. DEV. & STRATEGY |
Mar 11 '24 |
Sale |
65.81 |
20,000 |
1,316,200 |
273,226 |
CAREY STEPHEN P. | SVP & CFO |
Mar 11 '24 |
Sale |
65.55 |
7,787 |
510,438 |
177,712 |
Lalwani Nikhil | PRESIDENT & CEO |
Mar 08 '24 |
Sale |
67.13 |
16,292 |
1,093,682 |
411,629 |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.
Cap:
|
Volume (24h):